Virginia Commonwealth University
1000 E Broad Street
Richmond, VA 23219
United States
Led by Edmond P Wickham, MD, FAAP, the TrialNet team at Virginia Commonwealth University is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Note: As a TrialNet affiliate, Virginia Commonwealth University is regionally overseen by Vanderbilt University Medical Center. If you reach out to TrialNet, you may be contacted by staff from either institution.
Nuestro Equipo
Edmond Wickham, MD, FAAP
Principal InvestigatorDr. Wickham is a member of American Academy of Pediatrics, The Endocrine Society, The Obesity Society, and American Diabetes Association as well as the Pediatric Obesity Task Force of the Virginia Chapter of the American Association of Pediatrics.
Trang Le, MD
Sub- Investigator
Sarah Hensley, MD
Sub-Investigator
Erica Memoli, MS, RDN
Clinical Research Coordinator
Christian Rollison
Clinical Research CoordinatorEstudios de Investigación
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
TrialNet tested the drug abatacept to see if it could delay or prevent stage 1 T1D (two or more diabetes-related autoantibodies, but normal blood sugar) from progressing to stage 2 (abnormal blood sugar) or to stage 3 (clinical diagnosis). In an earlier study in people newly diagnosed (stage 3), participants treated with abatacept had 59% better insulin production and a 9.6-month average delay in progression of insulin loss compared to those who received placebo. That difference extended out to 3 years. Detalles
